|
WO2021075528A1
|
|
Method for evaluating drug toxicity
|
|
WO2021060380A1
|
|
Method for inducing hepatocyte plasticity
|
|
WO2020204149A1
|
|
Screening method and toxicity evaluation method
|
|
WO2020203713A1
|
|
Matrix composition
|
|
WO2020189561A1
|
|
Coating-securing agent
|
|
WO2020203015A1
|
|
Illness aggravation estimation system
|
|
WO2020175594A1
|
|
Composition for treating blood coagulation and/or complement disorders
|
|
WO2020149391A1
|
|
Method for evaluating differentiation resistance of undifferentiated cells
|
|
WO2020145231A1
|
|
Prophylactic and/or therapeutic agent for diseases accompanied by fibrosis
|
|
WO2020080270A1
|
|
Nutrition composition
|
|
WO2020059522A1
|
|
Reproductive medicine support system
|
|
WO2019240247A1
|
|
Undifferentiated cell detection method
|
|
WO2019203255A1
|
|
Drug evaluation method using reconstructed cancer tissue
|
|
WO2019203254A1
|
|
Cancer evaluation method using epithelial-mesenchymal-transition-related molecule
|
|
WO2019189324A1
|
|
Cell mass fusion method
|
|
EP3742166A1
|
|
Renal cancer detection method and test drug
|
|
WO2019131308A1
|
|
TREATMENT FOR ARRHYTHMIA USING 9-β-D-ARABINOFURANOSYLHYPOXANTINE
|
|
CN111417716A
|
|
Construction of three-dimensional organs from pluripotent stem cells
|
|
US2020318044A1
|
|
Method for aggregating cell mass and device for aggregating cell mass
|
|
CN111386335A
|
|
Construct for connecting structure body and cell mass
|
